| Not Yet Recruiting | Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initi Non Small Cell Lung Cancer (Stage III) | Phase 2 | 2026-05-10 |
| Not Yet Recruiting | Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progre Small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer NSCLC | Phase 2 | 2026-05-01 |
| Not Yet Recruiting | Megestrol Acetate for First-Line Treatment of Malnourished Non-Small Cell Lung Cancer Non-small Cell Lung Cancer | Phase 3 | 2026-04-01 |
| Recruiting | Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lun Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC) | Phase 3 | 2025-12-07 |
| Recruiting | The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer Non-small Cell Lung Cancer | — | 2025-12-02 |
| Not Yet Recruiting | Clinical Study of Nanocrystalline Megestrol in Malnourished Patients With First-Line Non-Small Cell Lung Cance Non Small Cell Lung Cancer | Phase 3 | 2025-05-01 |
| Not Yet Recruiting | Third-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TK Non-small Cell Lung Cancer | Phase 2 | 2024-11-30 |
| Not Yet Recruiting | Intrathecal Pemetrexed for SCLC Patients With Refractory Brain Metastases or Leptomeninges Metastatic Small-cell Lung Cancer | Phase 2 | 2024-10-01 |
| Not Yet Recruiting | AK112 Plus Platinum-based Chemotherapy for EGFR/ALK/ROS1 Positve NSCLC Efficacy | Phase 1 / Phase 2 | 2024-10-01 |
| Not Yet Recruiting | Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Met Non-small Cell Lung Cancer | Phase 2 | 2024-09-30 |
| Not Yet Recruiting | Bronchoscopic Cryoablation Combined With Chemo-Immunotherapy in NSCLC With Central Airway Obstruction Non-Small Cell Lung Cancer | Phase 2 | 2024-09-15 |
| Recruiting | Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW Non-small Cell Lung Cancer | Phase 2 | 2024-07-01 |
| Recruiting | Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced N Non-Small Cell Lung Cancer | Phase 2 | 2024-07-01 |
| Recruiting | Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK ALK Gene Mutation, Lung Adenocarcinoma, Immunotherapy | Phase 2 | 2024-05-29 |
| Recruiting | Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases Non-Small Cell Lung Cancer | Phase 2 | 2024-05-01 |
| Recruiting | The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC Non Small Cell Lung Cancer, RET Gene Mutation, MET Amplification | Phase 1 / Phase 2 | 2023-12-31 |
| Recruiting | A Study With Central Nervous System Metastatic EGFR Mutation Positive Non-small Cell Lung Cancer NSCLC | — | 2023-12-29 |
| Unknown | Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged Non Small Cell Lung Cancer | Phase 2 | 2023-12-25 |
| Unknown | Real-World Study on the Efficacy of IBI-322 in Combination With Lenvatinib for the Treatment of Extensive Stag Extensive-stage Small-cell Lung Cancer | — | 2023-12-25 |
| Recruiting | A Real-World Study of Atezolizumab in Combination With Platinum-Based Doublet Chemotherapy as Neoadjuvant Ther NSCLC | — | 2023-12-25 |
| Recruiting | The Efficacy and Safety of IBI363 in Solid Tumors Advanced Solid Tumor | Phase 1 / Phase 2 | 2023-12-25 |
| Recruiting | JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer Small-cell Lung Cancer | Phase 2 | 2023-06-01 |
| Recruiting | Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Sta Non Small Cell Lung Cancer | Phase 2 | 2023-02-01 |
| Recruiting | Immune Treatment of Brain Metastasis of Lung Cancer Combined With Large-segmentation Precision Radiotherapy Non Small Cell Lung Cancer | Phase 2 | 2022-12-25 |
| Recruiting | Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC Non-small Cell Lung Cancer | Phase 3 | 2022-09-23 |
| Completed | To Evaluate the Correlation Between the Results of Specific Gene Testing and the Efficacy of Targeted Therapy Non Small Cell Lung Cancer | — | 2022-09-20 |
| Recruiting | Compassionate Use Study of NHWD-870 in Patients With Advanced Solid Tumors or Lymphomas Carrying NUT Rearrange Advanced Solid Tumors or Lymphomas | — | 2022-09-20 |
| Completed | Association Between the Results of Specific Genetic Tests and the Efficacy of Targeted Therapies in Patients Non-small Cell Lung Cancer | — | 2022-06-30 |
| Recruiting | High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metas Non-Small Cell Lung Cancer | Phase 2 | 2022-05-01 |
| Recruiting | Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer Non Small Cell Lung Cancer | Phase 2 | 2022-04-01 |
| Unknown | Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung Cancer Small Cell Lung Cancer | Phase 2 | 2021-12-03 |
| Recruiting | ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma Non-small Cell Lung Cancer | Phase 2 | 2021-11-13 |
| Recruiting | Chemotherapy With or Without Immune Checkpoint Inhibitors for Lung Cancer Non Small Cell Lung Cancer | — | 2021-10-03 |
| Recruiting | Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors Lung Cancer | Phase 3 | 2021-10-01 |
| Completed | Chemotherapy Combined with ICIs in First-line Alectinib Failed Patients with ALK-rearranged NSCLC Non-small Cell Lung Cancer | Phase 2 | 2021-08-17 |
| Recruiting | The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined with Lenvatinib in NSCLC. Non-Small Cell Lung Cancer | Phase 2 | 2021-08-01 |
| Unknown | SHR-1701 Combined With Fluzoparib in Lung Squamous Cell Carcinoma Non-Small Cell Lung Cancer | Phase 2 | 2021-07-01 |
| Unknown | A Non-interventional Study With Advanced Lung Squamous Cell Carcinoma Advanced Lung Squamous Cell Carcinoma | — | 2021-07-01 |
| Unknown | Efficacy of Osimertinib in Patients With Lung Cancer Advanced Non-Small Cell Lung Cancer | — | 2021-01-01 |
| Completed | Antitumor Activity and Safety of BEBT-109, a Novel EGFR Inhibitor, in Previously Treated NSCLC NSCLC | Phase 1 | 2020-10-27 |
| Recruiting | Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation Non Small Cell Lung Cancer, EGFR Gene Mutation, ALK Gene Mutation | Phase 2 | 2020-04-16 |
| Recruiting | Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLC Non Small Cell Lung Cancer | — | 2020-03-24 |
| Recruiting | Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC Non-small Cell Lung Cancer | — | 2020-03-24 |
| Unknown | Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced NSCLC Patitnts: the POSEIDON T Non-small Cell Lung Cancer | — | 2020-03-24 |
| Recruiting | Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC Non-small Cell Lung Cancer | Phase 2 | 2020-03-24 |
| Recruiting | Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer Non-small Cell Lung Cancer | Phase 2 / Phase 3 | 2020-03-24 |
| Recruiting | Chemotherapy Combined With Immunotherapy in HER 2 Insertion or Amplification Advanced NSCLC Non Small Cell Lung Cancer | — | 2020-03-24 |
| Recruiting | A Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung Cancer Advanced Lung Cancer | — | 2020-01-01 |
| Completed | Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC Non-squamous NSCLC | — | 2019-09-01 |
| Completed | Efficacy Biomarker Investigation on Extensive Stage Small Cell Lung Cancer Extensive Stage Small Cell Lung Cancer | — | 2019-04-01 |
| Completed | Tumor Microenvironment Surveillance on Simultaneous Liver Metastases Extensive Stage Small Cell Lung Cancer Extensive Stage Small Cell Lung Cancer | — | 2019-04-01 |
| Completed | Phase II Study on Sintilimab Combined With Docetaxel for Chemotherapy Failure Advanced NSCLC: the SUCCESS Stud Non-small Cell Lung Cancer | Phase 2 | 2019-01-01 |
| Completed | Consistency of PD-L1 Detecting Method Between E1L3N and 22C3 Monoclonal Antibodies in NSCLC Patients Non Small Cell Lung Cancer | — | 2018-08-05 |
| Unknown | Real World Study on First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous Non-small Cell Lung Cancer Non-small Cell Lung Cancer | — | 2018-08-01 |
| Recruiting | Survival Outcomes of Lung Cancer Lung Cancer | — | 2018-08-01 |
| Unknown | Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Non Small Cell Lung Cancer | — | 2018-06-01 |
| Completed | The Prediction Biomarkers of Survival Outcome for Severe Immune-related Hepatitis Lung Cancer | — | 2018-05-01 |
| Completed | Efficacy and Safety of Immunotherapy in Non-small Cell Lung Cancer With Uncommon Histological Type Uncommon Pathological Types of Lung Cancer | — | 2018-03-02 |
| Completed | Local Radiotherapy for Residual Tumor Lesions During the First-line Treatment Non Small Cell Lung Cancer | — | 2018-01-02 |
| Unknown | Real World Study of First Line Crizotinib for ALK Rearranged Non-squamous Non-small Cell Lung Cancer Non-small Cell Lung Cancer | — | 2018-01-01 |
| Completed | Outcomes With Immune Checkpoint Inhibitor for Patients With Non-Small-Cell Lung Cancer and Stable Brain Metast Non Small Cell Lung Cancer | — | 2017-11-03 |
| Unknown | Intensity-modulated Radiotherapy (IMRT) With Simultaneous Integrated Boost (SIB) for Inoperable Non-small-cell Non-Small Cell Lung Cancer | Phase 2 | 2015-11-01 |
| Unknown | Polymorphisms in Key Genes of Glycolytic Pathway: Influence on Radiosensitivity in Nasopharyngeal Carcinoma Nasopharyngeal Carcinoma, Single Nucleotide Polymorphisms, Radiosensitivity | — | 2015-06-01 |
| Unknown | Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma Lung Adenocarcinoma | Phase 4 | 2015-05-01 |
| Unknown | Diffusion-weighted Magnetic Resonance Imaging (DW-MRI )for Early Response Assessment in Patients With Esophage Esophageal Carcinoma | — | 2014-10-01 |
| Unknown | Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers Carcinoma, Non-Small Cell Lung, EGFR Gene Mutation | Phase 2 | 2014-07-01 |
| Completed | Ethaselen for the Treatment of Thioredoxin Reductase High Expression Advanced Non-small Cell Lung Cancers Carcinoma, Non-small Cell Lung | Phase 1 | 2014-06-01 |
| Completed | Aprepitant for Chemotherapy Induced Nausea and Vomiting in Chinese Advanced Non-small Cell Lung Cancers Carcinoma, Non-small Cell Lung | Phase 3 | 2014-02-01 |
| Completed | Tumor Relapsed Study of Serum Trxr Activity in Advanced Non-small Cell Lung Cancer Advanced Non-small Cell Lung Cancer, First Line Treatment, Thioredoxin Reductase Activity | — | 2013-05-01 |
| Completed | Early Warning Study of Serum Thioredoixn Reductase Activity in Excised Non-small Cell Lung Cancers (EWSOTRILC) Non-small Cell Lung Cancer Stage I, Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage IIIA | — | 2013-05-01 |
| Completed | Correlation Research of Thioredoxin Reductase in Lung Cancer Non-small Cell Lung Cancer, Benign Neoplasm of Lung | — | 2013-05-01 |
| Unknown | Endostar Continued Pumping Into Vein Combining With Gemcitabine-Carboplatin to Treat Non-Small Cell Lung Cance Non-small Cell Lung Cancer | Phase 2 | 2011-08-01 |
| Completed | TS Gene Polymorphism Predicts Effect in Patients With Advanced Lung Cancer Non-small-cell Lung Cancer, Adenocarcinoma | Phase 2 | 2009-03-01 |